khondrion

KHENERFIN study

KHENERFIN is a Phase 3 study investigating whether sonlicromanol improves fatigue (lack of energy), muscle weakness, and other symptoms in people living with m.3243A>G PMD, including classic MELAS, MIDD and Mixed Phenotypes.

study design

Inactive tablet that looks just like the medication

KHENERFIN is a blinded, placebo-controlled study in which half of the patients will receive sonlicromanol and the other half placebo. The first wave of the study will include 40 participants; the second will include an additional 110 participants.

study locations

First wave study locations can be found here

khondrion

study features

concierge service

Door-to-door travel support for participants

convenient

At-home assesments and potential for at-home study visits

KHENERFIN
m.3243A>GPMD study

access

Half of the participants will receive sonlicromanol

extended access

Access to sonlicromanol for all participants in a planned compassionate use program

about sonlicromanol

Sonlicromanol is an investigational medicine that is taken as a twice-a-day oral tablet. Sonlicromanol has been studied in a Phase 1 study in healthy volunteers, in three studies (KHENERGY, KHENERGYZE AND KHENEREXT) in participants with m.3243A>G PMD and in one study (KHENERGYC) in children with PMD. A Named Patient Program with up to 2½ years favorable safety data is ongoing.

what's in a name (KHENERFIN)

KH stands for Khondrion who’s aim is to bring ENERGY back to patients. FIN stand for FINAL meaning that this study being the last study before market authorization.

khondrion

eligibility

To be considered for participation in KHENERFIN, the individuals must:

  • Be 18 years or older
  • Have an m.3243A>G multi-system PMD
  • Experience fatigue and muscle weakness

Final eligibility will be determined by the study doctor.

for more information

To learn more about KHENERFIN, contact study staff directly using the contact information provided on clinicaltrials.gov [NCT06451757] or email khenerfin@khondrion.com.